Market News & Trends
Calixar Invests in Pipeline of Highly Druggable Membrane Protein Targets & Native Antigens
Calixar recently announced its €1M ($1.2M) investment in a new pipeline of complex therapeutic targets and native antigens of high relevance for pharmaceutical companies. This…
CeQur Raises $115 Million to Support Commercialization & Scale-Up of Automated Manufacturing for CeQur Simplicity Wearable Insulin Delivery Device
CeQur recently announced the close of an oversubscribed $115-million equity financing. The company will use the funds to advance commercial plans for CeQur Simplicity, including…
Longeveron Announces Positive Results of Phase 1 Clinical Study of Lomecel-B Cell Therapy
Longeveron Inc. recently announced the final results of its Phase 1 clinical study evaluating the safety and efficacy of intravenous (IV) administration of Lomecel-B, an…
Akston Biosciences Launches Phase 1/2 Clinical Trial of Second-Generation COVID-19 Vaccine
Akston Biosciences Corporation recently announced the first participants have been dosed in an open-label trial of AKS-452, its COVID-19 vaccine candidate. The trial is managed…
Catalent Biologics Completes Madison Facility Expansion to Double Clinical & Commercial Drug Substance Capacity
Catalent recently announced it has completed the expansion of two new suites at its biologics drug substance development and manufacturing facility in Madison, WI, and…
Akouos Receives Orphan Drug & Rare Pediatric Disease Designations
Akouos, Inc. recently announced the US FDA has granted both Orphan Drug Designation (ODD) and Rare Pediatric Disease Designation (RPDD) for AK-OTOF, a gene therapy…
AEON Biopharma Doses First Patient in Phase 2 Trial of ABP-450 for the Treatment of Cervical Dystonia
AEON Biopharma, Inc. recently announced the initiation of patient dosing in a Phase 2 study of ABP-450 for the treatment of cervical dystonia. The company…
Yumanity Therapeutics Announces Study Demonstrating In Vivo Efficacy of YTX-7739 in a Glioblastoma Multiforme (GBM) Mouse Model
Yumanity Therapeutics recently announced results of a study that demonstrate in vivo efficacy, including increased median overall survival, of YTX-7739 in a mouse model for…
AzurRx BioPharma Initiates Phase 2 Clinical Trial of Niclosamide for the Treatment of COVID-19 Gastrointestinal Infections
AzurRx BioPharma, Inc. recently announced it has initiated its Phase 2 RESERVOIR clinical trial of a proprietary oral formulation of micronized niclosamide (FW-1022) for the…
uniQure Announces Completion of Enrollment in First Cohort of Phase 1/2 Clinical Trial of AMT-130 for the Treatment of Huntington’s Disease
uniQure recently announced the completion of patient enrollment in the first dose cohort of a randomized, double-blinded, Phase 1/2 clinical trial of AMT-130 for the…